Effects of streptozotocin on autoimmune diabetes in NOD mice

Clinical and Experimental Immunology

Volumn 134, Issue 2, 2003, Pages 210-216

  Koulmanda, M ^a   Qipo, A ^b   Auchincloss Jr , H ^a   Smith, R N ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Department of Surgery ^*

Author keywords

Autoimmunity; NOD mice; Regulatory T cells; Streptozotocin

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; MONOCLONAL ANTIBODY; STREPTOZOCIN;

ANIMAL MODEL; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; DIABETES MELLITUS; MOUSE; NONHUMAN; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; SCID MOUSE; SPLEEN CELL; STREPTOZOCIN DIABETES; T LYMPHOCYTE;

ANIMALS; AUTOIMMUNITY; CD8-POSITIVE T-LYMPHOCYTES; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; FEMALE; GRAFT REJECTION; ISLETS OF LANGERHANS TRANSPLANTATION; MALE; MICE; MICE, INBRED NOD; STREPTOZOCIN;

EID: 0242690090     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2003.02293.x     Document Type: Article

References (44)

1. Sibley RK, Sutherland DE, Goetz F, Michael AF. Recurrent diabetes mellitus in the pancreas iso - and allograft. A light and electron microscopic and immunohistochemical analysis of four cases. Laboratory Invest 1985; 53:132-44.
2. Drage M, Zaccone P, Phillips JM, Nicoletti F, Dawson J, Andrew Bradley J, Cooke A. Nondepleting anti-CD4 and soluble interleukin-1 receptor prevent autoimmune destruction of syngeneic islet grafts in diabetic NOD mice. Transplantation 2002; 74:611-9.
3. Koulmanda M, Qipo A, Smith RN, Auchincloss H Jr. Pig islet xenografts are resistant to autoimmune destruction by NOD recipients after anti-CD4 treatment. Xenotransplantation 2002; 9:1.
4. Okitsu T, Bartlett ST, Hadley GA, Drachenberg CB, Farney AC. Recurrent autoimmunity accelerates destruction of minor and major histoincompatible islet grafts in nonobese diabetic (NOD) mice. Am J Transplant 2001; 1:138-45.
5. Li XC, Zand MS, Li Y, Zheng XX, Strom TB. On histocompatibility barriers, Th1 to Th2 immune deviation, and the nature of the allograft responses. J Immunol 1998; 161:2241-7.
6. Makhlouf L, Kishimoto K, Smith RN, Abdi R, Koulmanda M, Winn HJ, Auchincloss H Jr, Sayegh MH. The Role of Autoimmunity in Islet Allograft Destruction. Major Histocompatibility Complex Class II Matching Is Necessary for Autoimmune Destruction of Allogeneic Islet Transplants After T-Cell Costimulatory Blockade. Diabetes 2002; 51:3202-10.
7. Salomon B, Bluestone JA. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol 2001; 19:225-52.
8. Atkinson MA, Leiter EH. The NOD mouse model of Type I diabetes: as good as it gets? Nat Med 1999; 5:601-4.
9. Delovitch TL, Singh B. The nonobese diabetic mouse as a model of autoimmune diabetes: immune dysregulation gets the NOD. Immunity 1997; 7:727-38.
10. Lakey JR, Singh B, Warnock GL, Rajotte RV. BCG immunotherapy prevents recurrence of diabetes in islet grafts transplanted into spontaneously diabetic NOD mice. Transplantation 1994; 57:1213-7.
11. Wang T, Singh B, Warnock GL, Rajotte RV. Prevention of recurrence of IDDM in islet-transplanted diabetic NOD mice by adjuvant immunotherapy. Diabetes 1992; 41:114-7.
12. Chatenoud L, Primo J, Bach JF. CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J Immunol 1997; 158:2947-54.
13. Sandberg JO, Eizirik DL, Sandler S. IL-1 receptor antagonist inhibits recurrence of disease after syngeneic pancreatic islet transplantation to spontaneously diabetic non-obese diabetic (NOD) mice. Clin Exp Immunol 1997; 108:314-7.
14. Ryu S, Kodama S, Ryu K, Schoenfeld DA, Faustman DL. Reversal of established autoimmune diabetes by restoration of endogenous beta cell function. J Clin Invest 2001; 108:63-72.
15. Wu Q, Salomon B, Chen M, Wang Y, Hoffman LM, Bluestone JA, Fu YX. Reversal of spontaneous autoimmune insulitis in nonobese diabetic mice by soluble lymphotoxin receptor. J Exp Med 2001; 193:1327-32.
16. Rabinovitch A, Suarez-Pinzon WL, Shapiro AM, Rajotte RV, Power R. Combination therapy with sirolimus and interleukin-2 prevents spontaneous and recurrent autoimmune diabetes in NOD mice. Diabetes 2002; 51:638-45.
17. Gregori S, Giarratana N, Smiroldo S, Uskokovic M, Adorini LA. 1alpha,25-dihydroxyvitamin D (3) analog enhances regulatory T-cells and arrests autoimmune diabetes in NOD mice. Diabetes 2002; 51:1367-74.
18. Bertry-Coussot L, Lucas B, Danel C, Halbwachs-Mecarelli L, Bach JF, Chatenoud L, Lemarchand P. Long-term reversal of established autoimmunity upon transient blockade of the LFA-1/intercellular adhesion molecule-1 pathway. J Immunol 2002; 168:3641-8.
19. Rayat GR, Singh B, Korbutt GS, Rajotte RV. Single injection of insulin delays the recurrence of diabetes in syngeneic islet-transplanted diabetic NOD mice. Transplantation 2000; 70:976-9.
20. Herold KC, Hagopian W, Auger JA et al. Anti-CD3 monoclonal antibody in new-onset Type I diabetes mellitus. N Engl J Med 2002; 346:1692-8.
21. Rossini AA, Like AA, Dulin WE, Cahill GF Jr. Pancreatic beta cell toxicity by streptozotocin anomers. Diabetes 1977; 26:1120-4.
22. Schnedl WJ, Ferber S, Johnson JH, Newgard CB. STZ transport and cytotoxicity. Specific enhancement in GLUT2-expressing cells. Diabetes 1994; 43:1326-33.
23. Turk J, Corbett JA, Ramanadham S, Bohrer A, McDaniel ML. Biochemical evidence for nitric oxide formation from streptozotocin in isolated pancreatic islets. Biochem Biophys Res Commun 1993; 197:1458-64.
24. Kroncke KD, Fehsel K, Sommer A, Rodriguez ML, Kolb-Bachofen V. Nitric oxide generation during cellular metabolization of the diabetogenic N-methyl-N-nitroso-urea streptozotozin contributes to islet cell DNA damage. Biol Chem Hoppe Seyler 1995; 376:179-85.
25. Yamamoto H, Uchigata Y, Okamoto H. Streptozotocin and alloxan induce DNA strand breaks and poly (ADP-ribose) synthetase in pancreatic islets. Nature 1981; 294:284-6.
26. Gotoh M, Maki T, Kiyoizumi T, Satomi S, Monaco AP. An improved method for isolation of mouse pancreatic islets. Transplantation 1985; 40:437-8.
27. Friedman T, Smith RN, Colvin RB, Iacomini J. A critical role for human CD4+ T-cells in rejection of porcine islet cell xenografts. Diabetes 1999; 48:2340-8.
28. Dialynas DP, Quan ZS, Wall KA, Pierres A, Quintans J, Loken MR, Pierres M, Fitch FW. Characterization of the murine T cell surface molecule, designated L3T4, identified by monoclonal antibody GK1.5. similarity of L3T4 to the human Leu-3/T4 molecule. J Immunol 1983; 131:2445-51.
29. Ghobrial RR, Boublik M, Winn HJ, Auchincloss H Jr. In vivo use of monoclonal antibodies against murine T cell antigens. Clin Immunol Immunopathol 1989; 52:486-506.
30. Barbara JA, Thrvey SE, Kingsley CI, Spriewald BM, Hara M, Witzke O, Morris PJ, Wood KJ. Islet allograft rejection can be mediated by CD4+, alloantigen experienced, direct pathway T cells of TH1 and TH2 cytokine phenotype. Transplantation 2000; 70:1641-9.
31. Yoon JW, Yoon CS, Lim HW et al. Control of autoimmune diabetes in NOD mice by GAD expression or suppression in beta cells. Science 1999; 284:1183-7.
32. Koulmanda M, Qipo A, Chebrolu S, O'Neil J, Auchincloss H, Smith RN. The effect of low versus high dose of streptozotocin in cynomolgus monkeys (Macaca fascicularis) Am J Transplant 2003; 3:267-72.
33. Christianson SW, Shultz LD, Leiter EH. Adoptive transfer of diabetes into immunodeficient NOD-scid/scid mice. Relative contributions of CD4+ and CDS+ T-cells from diabetic versus prediabetic NOD.NON-Thy-1a donors. Diabetes 1993; 42:44-55.
34. Balasa B, Krahl T, Patstone G, Lee J, Tisch R, McDevitt HO, Sarvetnick N. CD40 ligand-CD40 interactions are necessary for the initiation of insulitis and diabetes in nonobese diabetic mice. J Immunol 1997; 159:4620-7.
35. Herbelin A, Gombert JM, Lepault F, Bach JF, Chatenoud L. Mature mainstream TCR alpha beta+CD4+ thymocytes expressing 1-selectin mediate 'active tolerance' in the nonobese diabetic mouse. J Immunol 1998; 161:2620-8.
36. Mandel TE, Hoffman L, Collier S, Carter WM, Koulmanda M. Organ culture of fetal mouse and fetal human pancreatic islets for allografting. Diabetes 1982; 31:39-47.
37. Mandel TE, Koulmanda M. Effect of culture conditions on fetal mouse pancreas in vitro and after transplantation in syngeneic and allogeneic recipients. Diabetes 1985; 34:1082-7.
38. Abdi R, Smith RN, Makhlouf L, Najafian N, Luster AD, Auchincloss H Jr, Sayegh MH. The role of CC chemokine receptor 5 (CCR5) in islet allograft rejection. Diabetes 2002; 51:2489-95.
39. Takayama Y, Ichikawa T, Maki T. Effect of STZ administration on islet isograft and allograft survival in NOD mice. Diabetes 1993; 42:324-9.
40. Guo Z, Wu T, Kirchhof N, Mitai D, Williams JW, Azuma M. Sutherland DE, Hering BJ. Immunotherapy with nondepleting anti-CD4 monoclonal antibodies but not CD28 antagonists protects islet graft in spontaneously diabetic nod mice from autoimmune destruction and allogeneic and xenogeneic graft rejection. Transplantation 2001; 71:1656-65.
41. Molano RD, Berney T, Li H et al. Prolonged islet graft survival in NOD mice by blockade of the CD40-CD154 pathway of T-cell costimulation. Diabetes 2001; 50:270-6.
42. Hugues S, Mougneau E, Ferlin W et al. Tolerance to islet antigens and prevention from diabetes induced by limited apoptosis of pancreatic beta cells. Immunity 2002; 16:169-81.
43. Ferrari-Lacraz S, Zheng XX, Kim YS, Li Y, Maslinski W, Li XC, Strom TB. An antagonist IL-15/Fc protein prevents costimulation blockade-resistant rejection. J Immunol 2001; 167:3478-85.
44. Mandel TE. Transplantation of organ cultured fetal pancreas: Experimental studies and potential clinical application in diabetes mellitus. World J Surg 1984; 8:158-68.